Ispecimen Stock Today
| ISPC Stock | USD 1.08 0.05 4.85% |
PerformanceVery Weak
| Odds Of DistressVery High
|
ISpecimen is trading at 1.08 as of the 19th of July 2025, a 4.85 percent increase since the beginning of the trading day. The stock's open price was 1.03. ISpecimen has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 20th of April 2025 and ending today, the 19th of July 2025. Click here to learn more.
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts. The company has 2.5 M outstanding shares of which 44.28 K shares are currently shorted by private and institutional investors with about 0.99 trading days to cover. More on iSpecimen
Moving against ISpecimen Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
ISpecimen Stock Highlights
| Treasurer, CEO | Robert Lim |
| Old Name | Ispac 1 Ltd |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors) |
iSpecimen (ISPC) is traded on NASDAQ Exchange in USA. It is located in 8 Cabot Road, Woburn, MA, United States, 02420 and employs 24 people. ISpecimen is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.57 M. iSpecimen conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.5 M outstanding shares of which 44.28 K shares are currently shorted by private and institutional investors with about 0.99 trading days to cover.
iSpecimen currently holds about 23.69 M in cash with (8.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check ISpecimen Probability Of Bankruptcy
Ownership AllocationApproximately 94.9 (percent) of ISpecimen outstanding shares are held by general public with 2.7 % owned by insiders and only 2.4 pct. by outside corporations.
Check ISpecimen Ownership Details
iSpecimen Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. ISpecimen market risk premium is the additional return an investor will receive from holding ISpecimen long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.16) | |||
| Total Risk Alpha | (0.66) | |||
| Treynor Ratio | (0.12) |
ISpecimen Stock Against Markets
ISpecimen Corporate Management
| Emily Hubbard | VP Devel | Profile | |
| Benjamin Bielak | Chief Secretary | Profile | |
| Eric Langlois | Chief Officer | Profile | |
| Dawn Michelle | VP Operations | Profile | |
| Yuying Liang | Chief Officer | Profile | |
| Annette Arnold | Vice Development | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iSpecimen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade ISpecimen Stock refer to our How to Trade ISpecimen Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ISpecimen. If investors know ISpecimen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ISpecimen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of iSpecimen is measured differently than its book value, which is the value of ISpecimen that is recorded on the company's balance sheet. Investors also form their own opinion of ISpecimen's value that differs from its market value or its book value, called intrinsic value, which is ISpecimen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ISpecimen's market value can be influenced by many factors that don't directly affect ISpecimen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ISpecimen's value and its price as these two are different measures arrived at by different means. Investors typically determine if ISpecimen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ISpecimen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.